A combination immunotherapy for the patients with advanced or metastatic solid cancer

A combination immunotherapy for the patients with advanced or metastatic solid cancer - A combination immunotherapy for the patients with advanced or metastatic solid cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020440

Enrollment

Registered

2016-02-01

Start date

2016-01-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

solid cancer

Interventions

combination immunotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: solid cancer

Exclusion criteria

Exclusion criteria: Uncontroled general complication. etc

Design outcomes

Primary

Measure	Time frame
safety	—

Secondary

Measure	Time frame
1)specific CTL response 2)overall survival 3)progression-free survival 4)Response rate 5)disease control rate	—

Countries

Japan

Contacts

Public ContactNobuaki Suzuki

Yamaguchi university Graduate School of Medicine Department of Gastroenterological, Breast and Endocrine Surgery

geka2dm@yamaguchi-u.ac.jp0836-22-2264

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026